Editing cancer in vivo

Nicholas J. Bernard
DOI: https://doi.org/10.1038/s41590-024-01978-8
IF: 30.5
2024-09-28
Nature Immunology
Abstract:By overexpression of specific transcription factors, in vivo cell reprogramming has potential for treating 'cold' tumors that are often resistant to immune checkpoint blockade (ICB). A study in Science now shows that tumor cells in vivo can be reprogrammed to resemble type 1 conventional dendritic cells (cDC1s) and in so doing overcome these poorly immunogenic tumor conditions by boosting the presentation of tumor antigens. The researchers had previously found that the combination of the transcription factors PU.1, IRF8 and BATF3 (PIB) in vitro was sufficient to differentiate cancer cells in this manner, but they now demonstrate that this can be done in vivo using a gene-therapy approach in mouse melanoma models (and human spheroids). They injected replication-deficient viral vectors carrying PIB into the tumors and saw conversion of melanoma cells into cDC1-like cells with professional antigen-presenting capacity to activate anti-tumor T cell responses and limit tumor growth. In addition, the treatment resulted in immunological memory as there was durable protection against tumor rechallenge and against lung metastases. This method could avoid the costs and difficulties associated with ex vivo cell culture immunotherapies and boost or even replace ICB in resistant tumors. Original reference: Science https://doi.org/10.1126/science.adn9083 (2024)
immunology
What problem does this paper attempt to address?